Scholarlink

Background <p>This study aimed to determine the clinical impact of radiation response on survival in patients with medulloblastoma (MB) and to explore the predictive factor of radiation response.</p> Methods <p>Data from 170 pediatric patients with MB and residual disease or metastasis before radiotherapy (RT) were analyzed.</p> Results <p>The median follow-up period was 5.2 years. A total of 74 (43.5%) patients achieved CR, 85 (50.0%) patients achieved PR, 8 (4.7%) patients had SD, and 3 (1.8%) patients developed PD after RT. The five-year post-RT progression-free (prtPFS) and overall survival (prtOS) were superior in patients who achieved CR compared to those who did not (prtPFS: 67% ± 6% vs. 42% ± 6%, <i>P</i> &lt; 0.001; prtOS: 82% ± 5% vs. 44% ± 6%, <i>P</i> &lt; 0.001). Multivariable logistic regression analysis showed that residual disease site was the predictive factor for radiation response, patients who had residual disease in both the brain and spinal cord before RT had higher non-CR rate (OR: 7.312, 95%CI 3.375–15.845, <i>P</i> &lt; 0.001). Multivariate Cox analysis revealed that radiation response and large cell/anaplastic subtype were independent prognostic factors for survival (<i>P</i> &lt; 0.05).</p> Conclusions <p>Radiation response was an independent prognostic factor for survival in patients with MB. Patients who did not achieve CR after RT should receive intensified adjuvant chemotherapy to improve survival.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of radiation response on survival in pediatric medulloblastoma with residual or disseminated disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月11日

查看全文
  • Xuejiao Shi,
  • Xiaoyang Sun,
  • Wenqi Fan,
  • Xuan Dai,
  • Mawei Jiang

摘要

Background

This study aimed to determine the clinical impact of radiation response on survival in patients with medulloblastoma (MB) and to explore the predictive factor of radiation response.

Methods

Data from 170 pediatric patients with MB and residual disease or metastasis before radiotherapy (RT) were analyzed.

Results

The median follow-up period was 5.2 years. A total of 74 (43.5%) patients achieved CR, 85 (50.0%) patients achieved PR, 8 (4.7%) patients had SD, and 3 (1.8%) patients developed PD after RT. The five-year post-RT progression-free (prtPFS) and overall survival (prtOS) were superior in patients who achieved CR compared to those who did not (prtPFS: 67% ± 6% vs. 42% ± 6%, P < 0.001; prtOS: 82% ± 5% vs. 44% ± 6%, P < 0.001). Multivariable logistic regression analysis showed that residual disease site was the predictive factor for radiation response, patients who had residual disease in both the brain and spinal cord before RT had higher non-CR rate (OR: 7.312, 95%CI 3.375–15.845, P < 0.001). Multivariate Cox analysis revealed that radiation response and large cell/anaplastic subtype were independent prognostic factors for survival (P < 0.05).

Conclusions

Radiation response was an independent prognostic factor for survival in patients with MB. Patients who did not achieve CR after RT should receive intensified adjuvant chemotherapy to improve survival.